Table 1.
Basic characteristics.
| n = 192 | |
|---|---|
| Median age at diagnosis (years old), (range) | 53 ± 10.57 (29–81) |
| Body weight (kg) | 57 ± 10.18 (36–98) |
| Body mass index (BMI, kg/m2) | 23.0 ± 4.23 (15.8–40.3) |
| FIGO (Federation of Gynecology and Obstetrics) stage (2014) | |
| IIIA1 | 19 (9.9%) |
| IIIA2 | 10 (5.2%) |
| IIIB | 21 (10.9%) |
| IIIC | 100 (52.1%) |
| IVA | 13 (6.8%) |
| IVB | 29 (15.1%) |
| Cell type | |
| Serous | 123 (64.1%) |
| Mucinous | 8 (4.2%) |
| Seromucinous | 2 (1.0%) |
| Clear cell | 20 (10.4%) |
| Endometrioid | 12 (6.3%) |
| Brenner (including transitional cell carcinoma (TCC)) | 3 (1.6%) |
| Mixed type | 15 (7.8%) |
| Undifferentiated | 8 (4.2%) |
| Squamous cell | 1 (0.5%) |
| Surgical completeness | |
| Optimal debulking surgery | 100 (52.1%) |
| Sub-optimal debulking surgery | 75 (39.1%) |
| Biopsy or only cytology proof | 17 (8.9%) |
| Lymph nodes metastases | |
| Positive of metastases (pathology proof) | 75 (39.1%) |
| Negative of metastases (pathology proof) | 42 (21.9%) |
| No lymph nodes dissection or unknown | 75 (39.1%) |
| Adjuvant chemotherapy (for details, please refer to Table 2) | |
| GOG-158 | 144 (75.0%) |
| GOG-172 | 17 (8.9%) |
| JGOG-3016 | 5 (2.6%) |
| ICON-8 | 14 (7.3%) |
| GOG-218/ICON-7 | 12 (6.3%) |
| Recurrent status | |
| No | 48 (25.0%) |
| Yes | 117 (60.9%) |
| Persistent disease (no response to first line chemotherapy) | 27 (14.1%) |
| Survival status | |
| No evidence of disease (NED) | 47 (24.5%) |
| Alive with disease (AWD) | 74 (38.5%) |
| Died of disease (DOD) | 71 (37.0%) |
| Survival interval (months) | |
| Progression-free survival (PFS) | 17 ± 30.96 (0–167) |
| Overall survival (OS) | 39 ± 32.54 (4–167) |